Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies - PubMed (original) (raw)

Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies

Y Kido et al. Pharm Res. 2000 Jan.

Abstract

Purpose: To prove the functional significance of monocarboxylic acid transporter, MCT1 at the blood-brain barrier (BBB) for the passage of both endogenous and exogenous monocarboxylic acids into the central nervous system.

Methods: Monocarboxylic acid transport at the BBB was studied in rats by using a newly established immortalized brain capillary endothelial cell (BCEC) line, RBEC1, and the results were compared with those obtained by using primary cultured BCECs, cells stably expressed with rat MCT1, and the in vivo brain uptake index (BUI) method.

Results: The cell line, RBEC1 meets various morphological and enzymatic criteria of BCECs and appears to be suitable for the study of BBB transport of monocarboxylic acids. The presence of MCT1-transcript in RBEC1 was confirmnned by the RT-PCR method, as previously observed in isolated brain capillaries. A typical substrate of MCT1, lactic acid, was taken up by RBEC1 in a stereospecific and saturable manner. The value of the kinetic parameter Km showed good agreement with values previously obtained in studies using an in vivo BUI and in vitro MCT1-transfected cells. An organic weak acid, benzoic acid, which has been considered to cross biological membranes by passive diffusion, exhibited carrier-mediated transport properties, such as saturation, pH dependence, and stereospecific inhibition in RBEC1, similar to those we observed in primary cultured rat BCECs. The Km values in RBEC1, in primary cultured BCECs and in the in vivo BUI method were comparable and well agreed with that obtained in MCT1-transfected cells, suggesting that the transport features of benzoic acid observed by in vitro methods well reflect the in vivo transport activity. Furthermore, hybrid depletion of MCT1 in RBEC1 using an antisense oligonucleotide against rat MCT1 abolished the saturable transport of benzoic acid.

Conclusions: These observations show that MCT1 plays a significant role in the transport of monocarboxylic acids, including the exogenous organic weak acid benzoic acid, as well as native lactic acid.

PubMed Disclaimer

Similar articles

• Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1.
  Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A. Tamai I, et al. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. doi: 10.1211/0022357991776804. J Pharm Pharmacol. 1999. PMID: 10579682
• MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina.
  Hosoya K, Kondo T, Tomi M, Takanaga H, Ohtsuki S, Terasaki T. Hosoya K, et al. Pharm Res. 2001 Dec;18(12):1669-76. doi: 10.1023/a:1013310210710. Pharm Res. 2001. PMID: 11785685
• Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier.
  Kido Y, Tamai I, Uchino H, Suzuki F, Sai Y, Tsuji A. Kido Y, et al. J Pharm Pharmacol. 2001 Apr;53(4):497-503. doi: 10.1211/0022357011775794. J Pharm Pharmacol. 2001. PMID: 11341366
• Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions.
  Roux F, Couraud PO. Roux F, et al. Cell Mol Neurobiol. 2005 Feb;25(1):41-58. doi: 10.1007/s10571-004-1376-9. Cell Mol Neurobiol. 2005. PMID: 15962508 Review.
• Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport.
  Edmond J. Edmond J. J Mol Neurosci. 2001 Apr-Jun;16(2-3):181-93; discussion 215-21. doi: 10.1385/JMN:16:2-3:181. J Mol Neurosci. 2001. PMID: 11478373 Review.

Cited by

• Lower GLUT1 and unchanged MCT1 in Alzheimer's disease cerebrovasculature.
  Leclerc M, Tremblay C, Bourassa P, Schneider JA, Bennett DA, Calon F. Leclerc M, et al. J Cereb Blood Flow Metab. 2024 Aug;44(8):1417-1432. doi: 10.1177/0271678X241237484. Epub 2024 Mar 5. J Cereb Blood Flow Metab. 2024. PMID: 38441044 Free PMC article.
• In Vitro Blood-Brain Barrier Models for Neuroinfectious Diseases: A Narrative Review.
  Badawi AH, Mohamad NA, Stanslas J, Kirby BP, Neela VK, Ramasamy R, Basri H. Badawi AH, et al. Curr Neuropharmacol. 2024;22(8):1344-1373. doi: 10.2174/1570159X22666231207114346. Curr Neuropharmacol. 2024. PMID: 38073104 Free PMC article. Review.
• Stroke-induced damage on the blood-brain barrier.
  Xue S, Zhou X, Yang ZH, Si XK, Sun X. Xue S, et al. Front Neurol. 2023 Sep 28;14:1248970. doi: 10.3389/fneur.2023.1248970. eCollection 2023. Front Neurol. 2023. PMID: 37840921 Free PMC article. Review.
• Transporter-Mediated Drug Delivery.
  Gyimesi G, Hediger MA. Gyimesi G, et al. Molecules. 2023 Jan 24;28(3):1151. doi: 10.3390/molecules28031151. Molecules. 2023. PMID: 36770817 Free PMC article. Review.
• Orally Bioavailable Prodrugs of ψ-GSH: A Potential Treatment for Alzheimer's Disease.
  Xie W, Cao B, Zhu H, Raza A, Juckel N, Xie J, Jiang R, Vince R, Lee MK, More SS. Xie W, et al. J Med Chem. 2022 Nov 10;65(21):14441-14455. doi: 10.1021/acs.jmedchem.2c00779. Epub 2022 Oct 23. J Med Chem. 2022. PMID: 36353871 Free PMC article.

References

1. 1. J Pharmacobiodyn. 1990 Feb;13(2):158-63 - PubMed
2. 1. J Pharmacol Exp Ther. 1998 Jun;285(3):1175-80 - PubMed
3. 1. Biochem J. 1998 Jan 15;329 ( Pt 2):321-8 - PubMed
4. 1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21 - PubMed
5. 1. Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):178-87 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.